Press Releases

Home » Press Releases » Page 2
  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

2022-01-21T16:03:46+02:00January 21, 2022|Press Releases|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

2021-12-02T15:19:55+02:00December 2, 2021|Psychedelic News, Press Releases, Investor Information|

Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

  • Global Wellness Summit - Psilocybin - Boston

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

2021-11-27T05:48:16+02:00November 26, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing. 

Dr Dingle Spence to speak at two conferences on psychedelics

2021-10-13T13:40:15+02:00October 13, 2021|Press Releases, Investor Information|

Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.

  • Pure Psyence | Pure Extract | Psyence

Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts

2021-09-29T09:22:59+02:00September 28, 2021|Press Releases, Investor Information, Psychedelic News|

Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

2021-08-18T11:55:44+02:00August 18, 2021|Investor Information, Psychedelic News, Press Releases|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

2021-07-07T11:41:13+02:00July 7, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

Go to Top